Dr. Maya Guglin of the UK Gill Heart and Vascular Institute presented data at the American College of Cardiology's 67th Annual Scientific Session demonstrating that adding beta blockers or ACE inhibitors to a chemotherapy regimen for patients with HER2-positive breast cancer significantly reduces the risk of cardiotoxicity. Results from the trial have the potential to change the standard of care for HER2-positive breast cancer patients undergoing chemotherapy.
↧